• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新辅助治疗后乳腺癌残留疾病的治疗。

Treatment of residual disease following neoadjuvant therapy in breast cancer.

机构信息

Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, Illinois, USA.

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.

出版信息

J Surg Oncol. 2024 Jan;129(1):18-25. doi: 10.1002/jso.27523. Epub 2023 Nov 22.

DOI:10.1002/jso.27523
PMID:37990834
Abstract

Substantial advances have been made in the systemic treatment of breast cancer with residual disease following neoadjuvant therapy. We reviewed recent and ongoing studies informing the standard clinical management of residual disease by subtype: HER2+, TNBC, and HR+/HER2-, as well as strategies for BRCA+ disease. We conclude with a discussion of ongoing clinical trials and current controversies regarding the treatment of residual disease in breast cancer.

摘要

在新辅助治疗后有残留疾病的乳腺癌的系统治疗方面已经取得了重大进展。我们回顾了最近和正在进行的研究，这些研究为残留疾病的亚组（HER2+、TNBC 和 HR+/HER2-）的标准临床管理提供了信息，以及 BRCA+疾病的治疗策略。最后，我们讨论了正在进行的临床试验和当前关于乳腺癌残留疾病治疗的争议。

相似文献

1
Treatment of residual disease following neoadjuvant therapy in breast cancer.新辅助治疗后乳腺癌残留疾病的治疗。
J Surg Oncol. 2024 Jan;129(1):18-25. doi: 10.1002/jso.27523. Epub 2023 Nov 22.
2
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.激素受体阳性/人表皮生长因子受体 2 阴性乳腺癌患者新辅助化疗后残余增殖性癌症负担预测长期结局的验证。
Oncologist. 2020 Sep;25(9):e1355-e1362. doi: 10.1634/theoncologist.2020-0201. Epub 2020 Jul 21.
3
What is the best treatment recommendation for HER2+ IBC with residual disease?-a narrative review.对于存在残留病灶的 HER2+ IBC，最佳的治疗推荐是什么？——一篇叙述性综述
Chin Clin Oncol. 2021 Dec;10(6):59. doi: 10.21037/cco-21-122.
4
Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.术后CMF方案不能改善新辅助表柔比星/多西他赛化疗后仍有残留浸润性乳腺癌的女性患者的不良预后。
Clin Breast Cancer. 2015 Dec;15(6):505-11. doi: 10.1016/j.clbc.2015.06.007. Epub 2015 Jun 18.
5
Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy.新辅助化疗后不同表型乳腺癌女性的残余肿瘤负担分级与生存结局相关。
Ann Surg Oncol. 2022 Dec;29(13):8060-8069. doi: 10.1245/s10434-022-12300-x. Epub 2022 Aug 18.
6
Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy.新辅助化疗后残留乳腺癌的病理测量和分期。
Histopathology. 2023 Sep;83(3):453-464. doi: 10.1111/his.14966. Epub 2023 May 31.
7
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.新辅助化疗后与残留癌负荷及乳腺癌亚型相关的长期预后风险
J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30.
8
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.Alliance A011801（compassHER2 RD）：新辅助治疗后 T-DM1 联合或不联合 tucatinib/安慰剂治疗残留 HER2 阳性浸润性乳腺癌患者。
Future Oncol. 2021 Dec;17(34):4665-4676. doi: 10.2217/fon-2021-0753. Epub 2021 Oct 12.
9
Deciphering trastuzumab resistance in residual tumor according to HER2 status after neoadjuvant trastuzumab containing regimen in HER2 positive breast cancer patients might help to choose further adjuvant anti-HER2 treatment.在HER2阳性乳腺癌患者中，根据含曲妥珠单抗新辅助治疗方案后的HER2状态来解读残留肿瘤中的曲妥珠单抗耐药情况，可能有助于选择进一步的辅助抗HER2治疗。
J BUON. 2019 Sep-Oct;24(5):2208.
10
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.基于残余肿瘤负担、新辅助治疗反应指数和 Neo-Bioscore 评估的 HER2 阳性乳腺癌新辅助治疗后残余疾病的预后价值。
Clin Cancer Res. 2019 Aug 15;25(16):4985-4992. doi: 10.1158/1078-0432.CCR-19-0560. Epub 2019 May 10.

引用本文的文献

1
Clinical value of SUVpeak-to-tumor centroid distance on FDG PET/CT for predicting neoadjuvant chemotherapy response in patients with breast cancer.基于 FDG PET/CT 的 SUVpeak-肿瘤中心距离对乳腺癌新辅助化疗疗效预测的临床价值。
Cancer Imaging. 2024 Oct 11;24(1):136. doi: 10.1186/s40644-024-00787-4.
2
Navigating axillary staging post-neoadjuvant systemic therapy: innovations, efficacy, and oncologic safety.新辅助全身治疗后腋窝分期的探索：创新、疗效及肿瘤学安全性
Gland Surg. 2024 Jun 30;13(6):1146-1149. doi: 10.21037/gs-24-125. Epub 2024 Jun 26.